Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide-Reference-Cited by-同舟云学术

Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide

Published:2014-07-16 Issue:7512 Volume:512 Page:49-53
ISSN:0028-0836
Container-title:Nature
language:en
Short-container-title:Nature

Author:

Fischer Eric S.,Böhm Kerstin,Lydeard John R.,Yang Haidi,Stadler Michael B.,Cavadini Simone,Nagel Jane,Serluca Fabrizio,Acker Vincent,Lingaraju Gondichatnahalli M.,Tichkule Ritesh B.,Schebesta Michael,Forrester William C.,Schirle Markus,Hassiepen Ulrich,Ottl Johannes,Hild Marc,Beckwith Rohan E. J.,Harper J. Wade,Jenkins Jeremy L.,Thomä Nicolas H.

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/nature13527.pdf

Reference43 articles.

1. Bartlett, J. B., Dredge, K. & Dalgleish, A. G. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nature Rev. Cancer 4, 314–322 (2004)

2. Shortt, J., Hsu, A. K. & Johnstone, R. W. Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy. Oncogene 32, 4191–4202 (2013)

3. Melchert, M. & List, A. The thalidomide saga. Int. J. Biochem. Cell Biol. 39, 1489–1499 (2007)

4. McBride, W. G. Thalidomide and congenital abnormalities. Lancet 278, 1358 (1961)

5. Lenz, W., Pfeiffer, R. A., Kosenow, W. & Hayman, D. J. Thalidomide and congenital abnormalities. Lancet 279, 45–46 (1962)

Cited by 797 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunomodulation and anticancer evaluation of quinazoline-based thalidomide analogs: Design, synthesis, docking, and dynamic simulation;Journal of Molecular Structure;2024-12

2. Machine learning proteochemometric models for Cereblon glue activity predictions;Artificial Intelligence in the Life Sciences;2024-12

3. Pomalidomide sensitizes lung cancer cells to TRAIL/CDDP-induced apoptosis via directly targeting electron transfer flavoprotein alpha subunit;Bioorganic Chemistry;2024-12

4. Development of natural product-based targeted protein degraders as anticancer agents;Bioorganic Chemistry;2024-12

5. Inducing or enhancing protein-protein interaction to develop drugs: Molecular glues with various biological activity;European Journal of Medicinal Chemistry;2024-11